Darwin Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 0.92 M
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2016
- Satisfied Charges ₹ 5.70 M
- Revenue Growth -55.38%
- Profit Growth -46.24%
- Ebitda 110.35%
- Net Worth 2.54%
- Total Assets 146.35%
About Darwin Pharma
Darwin Pharma Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 July 2009 and has a history of 15 years and six months. Its registered office is in Krishna, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 0.92 M.
The company has closed loans amounting to ₹5.70 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
China Surasani, Raja Lankeyreddy, and Ravikiran Devineni serve as directors at the Company.
Company Details
-
Location
Krishna, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397AP2009PTC064584
-
Company No.
064584
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Jul 2009
-
Date of AGM
30 Sep 2016
-
Date of Balance Sheet
31 Mar 2016
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Darwin Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
China Surasani
|
Managing Director | 31-Jul-2009 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Raja Lankeyreddy
|
Director | 02-Mar-2015 | Current |
|
Ravikiran Devineni
|
Director | 15-Jul-2015 | Current |
Financial Performance of Darwin Pharma.
Darwin Pharma Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 55.38% decrease. The company also saw a substantial fall in profitability, with a 46.24% decrease in profit. The company's net worth moved up by a moderate rise of 2.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darwin Pharma?
In 2016, Darwin Pharma had a promoter holding of 43.72% and a public holding of 56.28%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0.57 Cr
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.57 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Oct 2010 | Indian Overseas Bank | ₹5.70 M | Satisfied |
How Many Employees Work at Darwin Pharma?
Unlock and access historical data on people associated with Darwin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Darwin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Darwin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
